ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 2004, p. 364–365 Vol. 48, No. 1
0066-4804/04/$08.00+0 DOI: 10.1128/AAC.48.1.364–365.2004

Type 1 Integrons in Epidemiologically Unrelated *Acinetobacter baumannii* Isolates Collected at Spanish Hospitals

Acinetobacter baumannii is an opportunistic nosocomial pathogen, which is an important cause of pneumonia and bacteremia in patients in intensive care units (1). Increased resistance to all commercial antimicrobial agents, including colistin, in clinical isolates of *A. baumannii* has been reported (7, 12). An important factor for the development of multiresistance is the acquisition of genetic elements, such as integrons (6). Different reports have been published, identifying integrons as responsible for the presence and acquisition of antibiotic resistance in members of the genus *Acinetobacter* (2, 3, 5, 8, 9, 10, 13).

The aim of this study was to investigate the role of type 1 integrons in mediating antibiotic resistance in Spanish clinical isolates of *A. baumannii*. Moreover, the epidemiological relationship between Spanish isolates containing type 1 integrons and seven isolates from Italian hospitals containing the same integrons was determined.

For this purpose, 69 epidemiologically unrelated *A. baumannii* isolates were collected during November 2000 from 28 Spanish hospitals. All isolates were identified by amplified ribosomal DNA restriction analysis (11), and their epidemiological relationship was determined by pulsed-field gel electrophoresis (PFGE), following the method of Gautom (4).

PCR amplification of type 1 integrons was done using the set of primers described by Ploy et al. (8) following conditions and procedures that will be published elsewhere (9). DNA sequencing of the inserted gene cassettes was performed with the dRhodamine terminator cycle sequencing kit and was analyzed in an automatic DNA sequencer (ABI Prism 377; Perkin-Elmer, Emeryville, Calif.)

Of a total of 69 *A. baumannii* isolates, 19 (27.53%) possessed type 1 integrons. Fifteen of these 19 (78.94%) isolates showed the presence of a 700-bp band containing a single *aadB* allele (Table 1). One of the 19 isolates (5.26%) yielded an amplification product of approximately 2,400 bp (Table 1) with three gene cassettes, an *aacA4* allele, an open reading frame (ORF) coding for a yet undetermined product named OrfO, and the bla_{OXA-20} gene (5, 8). Two of the 19 isolates (10.52%) gave an amplification product of approximately 800 bp (Table 1). Direct sequencing of this amplicon revealed the presence of a single gene cassette that contained an *aacA4* gene, which was identical to that found in the integron mentioned above. Of the two isolates containing this integron, one was resistant to both tobramycin and amikacin, while the other isolate was resistant to tobramycin but was susceptible to amikacin. These results agreed with those found by Ploy et al. (8) who found two isolates with the same integron but susceptible to amikacin. Only one isolate (5.26%) showed an amplicon of approximately 2,800 bp containing four gene cassettes (Table 1), an *aacC1* determinant, followed by two ORFs that code for unknown products and that are carried on two cassettes (5), and an *aadA1a* gene. To our knowledge, this type of integron carrying four gene cassettes has been described only once and is found in Italian isolates (5).

TABLE 1. Integron gene composition related to the phenotype of resistance found in *A. baumannii* clinical isolates

No. of isolates (n = 19)	Amplicon size (bp)	Resistance gene(s)	Resistance phenotype[a]
15	700	*aadB*	GEN, TOB
1	2,400[b]	*aacA4*, ORF O, bla_{OXA-20}	AMK, TOB, β-Lactams
2	800[b]	*aacA4*	TOB
1	2,800[b]	*aacC1*, ORF X, ORF X′, *aadA1a*	GEN

[a] Abbreviations: GEN, gentamicin; TOB, tobramycin; AMK, amikacin.
[b] Gene cassettes found in Italian isolates.

The integrons of 800, 2,400, and 2,800 bp, were found in Italian *A. baumannii* isolates. In order to elucidate whether Italian isolates with the same type of integrons (5) possessed the same clonal origin as the Spanish clinical isolates of *A. baumannii*, a PFGE was performed. The results showed that all the isolates were not epidemiologically related.

In conclusion, our results reflect the potential risk of antimicrobial resistance dissemination, both within and between unrelated species. Moreover, we demonstrate that nonrelated isolates from different geographic areas are able to acquire common integrons, leading to the question of whether *A. baumannii* has a clear affinity for a specific type of integron.

A.R. has a fellowship from the Ministerio de Educación y Ciencia of Spain. This work has been supported in part by a research grant from Merck Sharp & Dohme in Madrid, Spain. We thank Lucilla Dolzani (Dipartimento di Scienze Biomediche, Sezione di Microbiologia, Università di Trieste, Trieste, Italy) for providing us with the Italian clinical isolates of *A. baumannii*. We also thank the Red Española de Investigación en Patología Infecciosa C03/14 (Ministerio de Sanidad of Spain) for some financial support.

The members of the Spanish Group of Nosocomial Infections (GEIH) of the Spanish Society of Infectious Diseases and Clinical Microbiology are as follows: Javier Ariza, M. Angeles Domínguez, Miquel Pujol, and Fe Tubau (Hospital Universitario de Bellvitge, Barcelona, Spain); Juan Pablo Horcajada, Anna Ribera, and Jordi Vila (Hospital Clinic, Barcelona, Spain); Jordi Cuquet, Carmina Martí, and Dolors Navarro (Hospital General de Granollers, Barcelona, Spain); Francisco Alvarez Lerma and Margarita Salvadó (Hospital del Mar, Barcelona, Spain); Fernando Chaves and Antonio Sánchez Porto (Hospital de la Línea de la Concepción, Cádiz, Spain); Fernando Rodríguez López and Elisa Vidal (Hospital Universitario Reina Sofía, Córdoba, Spain); Alejandro Beceiro and German Bou (Hospital Juan Canalejo, A Coruña, Spain); Manuel de la Rosa (Hospital Virgen de las Nieves, Granada, Spain); Fernando Chaves and Manuel Lisazoain (Hospital Doce de Octubre, Madrid, Spain); Paloma García Hierro and Josefa Gómez Castillo (Hospital de Getafe, Madrid, Spain); Belen Padilla (Hospital Gregorio Marañón, Madrid, Spain); Jesús Martínez Beltrán (Hospital Ramón y Cajal, Madrid, Spain); Manuel López Brea and Lucía Pérez (Hospital Universitario de la Princesa, Madrid, Spain); Manuel Causse and Pedro Manchado (Centro Hospitalario Carlos Haya, Málaga, Spain); Inés Dorronsoro and José Javier García Irure (Clínica de Navarra, Navarra, Spain); Almudena Tinajas (Complejo Hospitalario de Orense, Orense, Spain); Gloria Esteban and Begoña Fernández (Hospital Santa María de Nai, Orense, Spain); Nuria Borrell and Antonio Ramírez (Hospital Son Dureta, Palma de

Mallorca, Spain); Isabel Alamo and Diana García Bardeci (Hospital del Pino, Las Palmas de Gran Canaria, Spain); José Angel García Rodríguez (Hospital Universitario, Salamanca, Spain); Carmen Fariñas and Carlos Fernández Mazarrasa (Hospital Marqués de Valdecilla, Santander, Spain); Eduardo Varela and Mercedes Treviño (Hospital Universitario, Santiago de Compostela, Spain); Luis Martínez, Alvaro Pascual, and Jesús Rodríguez Baño (Hospital Universitario Virgen Macarena, Seville, Spain); Ana Barreros, José Miguel Cisneros, Jerónimo Pachón, and Trinidad Prados (Hospitales Universitarios Virgen del Rocío, Seville, Spain); Frederic Ballester (Hospital Universitario de Reus, Tarragona, Spain); María Eugenia García Leoni and Ana Leturia (Centro Nacional de Parapléjicos, Toledo, Spain); Susana Brea and Enriqueta Muñoz (Hospital Virgen de la Salud, Toledo, Spain); and Joaquina Sevillano and Irene Rodríguez Conde (Povisa, Vigo, Spain).

REFERENCES

1. **Bergogne-Berezin, E., and K. J. Towner.** 1996. *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin. Microbiol. Rev. **9:**148–165.
2. **Chu, Y.-W., M. Afzal-shah, E. T. S. Houang, M.-F. I. Palepou, D. J. Lyon, N. Woodford, and D. Livermore.** 2001. IMP-4, a novel metallo-β-lactamase from nosocomial *Acinetobacter* spp. collected in Hong Kong between 1994 and 1998. Antimicrob. Agents Chemother. **45:**710–714.
3. **Gallego, L., and K. J. Towner.** 2001. Carriage of class 1 integrons and antibiotic resistance in clinical isolates of *Acinetobacter baumannii* from northern Spain. J. Med. Microbiol. **50:**71–77.
4. **Gautom, R. K.** 1997. Rapid pulsed-field gel electrophoresis protocol for typing of *Escherichia coli* O157:H7 and other gram-negative organisms in 1 day. J. Clin. Microbiol. **35:**2977–2980.
5. **Gombac, F., M. L. Riccio, G. M. Rossolini, C. Lagatolla, E. Tonin, C. Monti-Bragadin, A. Lavenia, and L. Dolzani.** 2002. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of *Acinetobacter baumannii* from Italian hospitals reveals a limited diversity of gene cassette arrays. Antimicrob. Agents Chemother. **46:**3665–3668.
6. **Hall, R. M., and C. M. Collis.** 1998. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist. Updates **1:**109–119.
7. **Levin, A. S., A. A. Barone, J. Penco, M. V. Santos, I. S. Marinho, E. A. Arruda, E. I. Manrique, and S. F. Costa.** 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Clin. Infect. Dis. **28:**1008–1011.
8. **Ploy, M. C., F. Denis, P. Courvalin, and T. Lambert.** 2000. Molecular characterization of integrons in *Acinetobacter baumannii*: description of a hybrid class 2 integron. Antimicrob. Agents Chemother. **44:**2684–2688.
9. **Ruiz, J., M. M. Navia, C. Casals, J. M. Sierra, M. T. Jiménez de Anta, and J. Vila.** 2003. Integron-mediated antibiotic multiresistance in *Acinetobacter baumannii* clinical isolates from Spain. Clin. Microbiol. Infect. **9:**907–911.
10. **Segal, H., and B. G. Elisha.** 1997. Identification and characterization of an *aadB* gene cassette at a secondary site in a plasmid from *Acinetobacter*. FEMS Microbiol. Lett. **153:**321–326.
11. **Vaneechoutte, M., L. Dijkshoorn, I. Tjernberg, A. Elaichouni, P. de Vos, G. Claeys, and G. Verschraegen.** 1995. Identification of *Acinetobacter* genomic species by amplified ribosomal DNA restriction analysis. J. Clin. Microbiol. **33:**11–15.
12. **Vila, J., M. A. Marcos, F. Marco, S. Abdalah, Y. Vergara, R. Reig, R. Gómez-Lus, and M. T. Jiménez de Anta.** 1993. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase and susceptibility of clinical isolates of *Acinetobacter baumannii*. Antimicrob. Agents Chemother. **37:**138–141.
13. **Yum, J. H., K. Yi, H. Lee, D. Yong, K. Lee, J. M. Kim, G. M. Rossolini, and Y. Chong.** 2002. Molecular characterization of metallo-β-lactamase-producing *Acinetobacter baumannii* and *Acinetobacter* genomospecies 3 from Korea: identification of two new integrons carrying the bla_{VIM-2} gene cassettes. J. Antimicrob. Chemother. **49:**837–840.

A. Ribera
J. Vila*
Servei de Microbiologia
Institut Clínic Infeccions i Immunologia
IDIBAPS
Hospital Clínic
Villarroel 170
08036 Barcelona, Spain

F. Fernández-Cuenca
L. Martínez-Martínez, and
A. Pascual
Servicio de Microbiología Hospital Virgen de la Macarena
Avda. Sanchez Pizjuan, s/n
41071 Seville, Spain

A. Beceiro, and
G. Bou
Servicio de Microbiología
Hospital Juan Canalejo
Xubias de Arriba 84
La Coruña, Spain

J. M. Cisneros, and
J. Pachón
Servicio de Enfermedades Infecciosas
Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n
41013 Seville, Spain

J. Rodríguez-Baño
Servicio de Enfermedades Infecciosas Hospital Vírgen de la Macarena
Avda. Sanchez Pizjuan, s/n
41071 Seville, Spain

Spanish Group for Nosocomial Infection (GEIH)†

*Phone: 34-932275522
Fax: 34-932279372
E-mail: vila@medicina.ub.es

† Members of the Spanish Group for Nosocomial Infection (GEIH) are listed in Acknowledgments.